X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (80) 80
male (64) 64
cardiac & cardiovascular systems (59) 59
female (57) 57
middle aged (53) 53
aged (44) 44
treatment outcome (30) 30
mortality (26) 26
myocardial infarction - therapy (26) 26
adult (24) 24
time factors (24) 24
electrocardiography (23) 23
follow-up studies (22) 22
myocardial infarction - mortality (21) 21
angioplasty (19) 19
risk factors (19) 19
thrombolytic therapy (19) 19
coronary angiography (18) 18
index medicus (18) 18
prognosis (18) 18
angioplasty, balloon, coronary (17) 17
reperfusion (17) 17
myocardial infarction (16) 16
recurrence (15) 15
double-blind method (14) 14
prospective studies (14) 14
drug therapy (13) 13
heart attack (13) 13
heart attacks (13) 13
platelet aggregation inhibitors - therapeutic use (13) 13
abciximab (12) 12
acute myocardial infarction (12) 12
acute myocardial-infarction (12) 12
fibrinolytic agents - therapeutic use (12) 12
tissue plasminogen activator - therapeutic use (12) 12
transluminal angioplasty (12) 12
angiography (11) 11
anticoagulants (11) 11
anticoagulants - therapeutic use (11) 11
cardiac catheterization (11) 11
heparin - therapeutic use (11) 11
myocardial infarction - drug therapy (11) 11
percutaneous coronary intervention (11) 11
survival analysis (11) 11
thrombolysis (11) 11
cardiovascular (10) 10
coronary heart disease (10) 10
therapy (10) 10
unstable angina (10) 10
acute coronary syndromes (9) 9
antibodies, monoclonal - therapeutic use (9) 9
cardiac patients (9) 9
cardiology (9) 9
hemorrhage - chemically induced (9) 9
immunoglobulin fab fragments - therapeutic use (9) 9
myocardial infarction - complications (9) 9
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (9) 9
primary angioplasty (9) 9
recombinant proteins - therapeutic use (9) 9
risk assessment (9) 9
streptokinase (9) 9
angioplasty, balloon, coronary - adverse effects (8) 8
angioplasty, balloon, coronary - methods (8) 8
combined modality therapy (8) 8
medicine, general & internal (8) 8
myocardial infarction - diagnosis (8) 8
aged, 80 and over (7) 7
coronary artery bypass (7) 7
coronary disease - therapy (7) 7
heparin (7) 7
immediate angioplasty (7) 7
myocardial-infarction (7) 7
peripheral vascular disease (7) 7
randomized controlled trials as topic (7) 7
tissue plasminogen activator (7) 7
trial (7) 7
abridged index medicus (6) 6
artery disease (6) 6
care and treatment (6) 6
complications (6) 6
health aspects (6) 6
intervention (6) 6
ischemia (6) 6
medical and health sciences (6) 6
medicin och hälsovetenskap (6) 6
myocardial infarction - physiopathology (6) 6
patient outcomes (6) 6
randomized trial (6) 6
recombinant proteins - adverse effects (6) 6
reperfusion therapy (6) 6
stents (6) 6
thrombin (6) 6
tissue plasminogen activator - administration & dosage (6) 6
tissue plasminogen-activator (6) 6
cardiovascular diseases (5) 5
coronary angioplasty (5) 5
coronary vessels (5) 5
drug therapy, combination (5) 5
evaluation (5) 5
exercise test (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2008, Volume 358, Issue 21, pp. 2205 - 2217
Immediate percutaneous coronary intervention (PCI) is the treatment of choice for acute ST-segment elevation myocardial infarction. In this study, PCI that was... 
IMMEDIATE ANGIOPLASTY | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | TO-BALLOON TIME | 30-DAY MORTALITY | INTRAVENOUS THROMBOLYTIC THERAPY | RISK PATIENTS | REPERFUSION THERAPY | SYMPTOM-ONSET | PRIMARY ANGIOPLASTY | FIBRINOLYTIC THERAPY | Myocardial Infarction - mortality | Myocardial Infarction - classification | Humans | Immunoglobulin Fab Fragments - adverse effects | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Immunoglobulin Fab Fragments - therapeutic use | Recombinant Proteins - adverse effects | Tissue Plasminogen Activator - adverse effects | Angioplasty, Balloon, Coronary | Fibrinolytic Agents - adverse effects | Myocardial Infarction - therapy | Time Factors | Electrocardiography | Female | Cerebral Infarction - chemically induced | Double-Blind Method | Kaplan-Meier Estimate | Tissue Plasminogen Activator - administration & dosage | Treatment Outcome | Combined Modality Therapy | Recombinant Proteins - administration & dosage | Myocardial Infarction - complications | Aged | Fibrinolytic Agents - administration & dosage | Hemorrhage - chemically induced | Care and treatment | Abciximab | Coronary artery bypass | Comparative analysis | Health aspects | Heart attack | Angioplasty | Heart attacks | Intubation | Index Medicus | Abridged Index Medicus
Journal Article
European Heart Journal Supplements, ISSN 0195-668X, 11/2008, Volume 10, Issue suppl_I, pp. I30 - I32
Significant advances have been made over the last several years in the treatment of patients with acute coronary syndromes including the introduction and... 
Atherothrombotic trials | Glycoprotein IIb/IIIa inhibitors | Clopidogrel | Percutaneous coronary intervention | Heparin | Acute coronary syndrome | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | ACUTE CORONARY SYNDROMES | INTERVENTION
Journal Article
European Heart Journal, ISSN 0195-668X, 12/2008, Volume 29, Issue 23, pp. 2909 - 2945
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 2005, Volume 95, Issue 1, pp. 100 - 101
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 2009, Volume 2, Issue 10, pp. 917 - 924
Objectives We hypothesized that patients most likely to benefit would be those at high risk with a shorter duration of acute ischemia and who required transfer... 
Cardiovascular | percutaneous coronary intervention | STEMI facilitation | TRIALS | RETEPLASE | CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | SCORE | NATIONAL-REGISTRY | REPERFUSION | ABCIXIMAB | PRIMARY ANGIOPLASTY | Recombinant Proteins - therapeutic use | Myocardial Infarction - mortality | Humans | Immunoglobulin Fab Fragments - adverse effects | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Tissue Plasminogen Activator - therapeutic use | Immunoglobulin Fab Fragments - therapeutic use | Recombinant Proteins - adverse effects | Tissue Plasminogen Activator - adverse effects | Angioplasty, Balloon, Coronary - adverse effects | Fibrinolytic Agents - adverse effects | Myocardial Infarction - therapy | Multicenter Studies as Topic | Angioplasty, Balloon, Coronary - mortality | Time Factors | Health Services Accessibility | Fibrinolytic Agents - therapeutic use | Retrospective Studies | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Double-Blind Method | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Combined Modality Therapy | Thrombolytic Therapy - mortality | Randomized Controlled Trials as Topic | Hemorrhage - chemically induced | Thrombolytic Therapy - adverse effects | Patient Transfer | Index Medicus
Journal Article
European Heart Journal, ISSN 0195-668X, 04/2010, Volume 31, Issue 8, pp. 943 - 957
Journal Article
Journal Article